These approvals grant access to two markets renowned for their expertise in interventional gastroenterology and are part of the new commercial organization unveiled on February 4, 2026, aimed at accelerating growth outside the United States.

In the wake of these developments, the group has received a first order from Inselspital in Bern, which will be equipped with a Cellvizio Gen3 dedicated to functional disorders related to the intestinal barrier.

Sacha Loiseau, Chairman and Chief Executive Officer, emphasized that "these markets represent an immediate opportunity for Cellvizio and CellTolerance," and sees the Bern order as "a first tangible sign of this momentum."